Investment of Approx. USD 4.5 Million in Development of Diagnostics for Tuberculosis to Partners Including Fujirebio and University Hospital Heidelberg
TOKYO, April 23, 2025 /PRNewswire/ — The Global Health Innovative Technology (GHIT) Fund announced…
Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA
– ASC30 oral once-daily tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction…